Esperion Therapeutics ESPR EBITDA margin
EBITDA margin at other companies
Other financials
Where this comes from
Calculated from Esperion Therapeutics’s reported figures.
Based on trailing twelve months.
The official record: Esperion Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Esperion Therapeutics's ebitda margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Esperion Therapeutics's EBITDA margin?
- Esperion Therapeutics (ESPR) reported EBITDA margin of 18.1% in Q1 2026.
- How has Esperion Therapeutics's EBITDA margin changed year-over-year?
- Esperion Therapeutics's EBITDA margin increased by 232.9% year-over-year, from -13.7% to 18.1%.
- What is the long-term trend for Esperion Therapeutics's EBITDA margin?
- Over 5 years (2020 to 2025), Esperion Therapeutics's EBITDA margin has grown at a -22.4% compound annual growth rate (CAGR), from -53.1% to 15%.
- What does EBITDA margin mean?
- EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.